Clinical trialNCT02141399CompletedPhase 3Interventional

A Long-Term Safety Study of ALKS 5461

SponsorAlkermes, Inc.Enrollment1,485Major Depressive Disorder

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sanjeev Pathak, MD
Alkermes, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

158 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Alkermes Investigational Site
Towong, Queensland, Australia
Alkermes Investigational Site
Frankston, Victoria, Australia
Alkermes Investigational Site
Melbourne, Victoria, Australia

Bulgaria

Alkermes Investigational Site
Burgas, Bulgaria
Alkermes Investigational Site
Kazanlak, Bulgaria
Alkermes Investigational Site
Sofia, Bulgaria
Alkermes Investigational Site
Sofia, Bulgaria
Alkermes Investigational Site
Sofia, Bulgaria
Alkermes Investigational Site
Varna, Bulgaria
Alkermes Investigational Site
Veliko Tarnovo, Bulgaria
Alkermes Investigational Site
Vratsa, Bulgaria

Canada

Alkermes Investigational Site
Penticton, British Columbia, Canada
Alkermes Investigational Site
Halifax, Nova Scotia, Canada
Alkermes Investigational Site
Gatineau, Quebec, Canada
Alkermes Investigational Site
Québec, Canada

Germany

Alkermes Investigational Site
Oranienburg, Brandenburg, Germany
Alkermes Investigational Site
Achim, Germany
Alkermes Investigational Site
Berlin, Germany
Alkermes Investigational Site
Berlin, Germany
Alkermes Investigational Site
Berlin, Germany
Alkermes Investigational Site
Ellwangen, Germany
Alkermes Investigational Site
Freiburg im Breisgau, Germany
Alkermes Investigational Site
Hanover, Germany
Alkermes Investigational Site
Mainz, Germany
Alkermes Investigational Site
Schwerin, Germany
Alkermes Investigational Site
Stralsund, Germany

Hungary

Alkermes Investigational Site
Budapest, Hungary
Alkermes Investigational Site
Budapest, Hungary
Alkermes Investigational Site
Budapest, Hungary

Poland

Alkermes Investigational Site
Bialystok, Poland
Alkermes Investigational Site
Gdansk, Poland
Alkermes Investigational Site
Gdansk, Poland
Alkermes Investigational Site
Gorlice, Poland

Puerto Rico

Alkermes Investigational Site
San Juan, Puerto Rico
Alkermes Investigational Site
San Juan, Puerto Rico

United States

Alkermes Investigational Site
Birmingham, Alabama, United States
Alkermes Investigational Site
Birmingham, Alabama, United States
Alkermes Investigational Site
Tucson, Arizona, United States
Alkermes Investigational Site
Little Rock, Arkansas, United States
Alkermes Investigational Site
Bellflower, California, United States

118 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2014
Primary completion: 20 Nov 2017
Completion: 20 Nov 2017
Last update posted: 14 Dec 2018
Registered enrollment: 1,485
Registry id: NCT02141399

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.